Ischemia/Reperfusion Injury in Liver Surgery and Transplantation: Pathophysiology by Weigand, Kilian et al.
Hindawi Publishing Corporation
HPB Surgery
Volume 2012, Article ID 176723, 8 pages
doi:10.1155/2012/176723
Review Article
Ischemia/ReperfusionInjury in Liver Surgery
and Transplantation: Pathophysiology
KilianWeigand,1 SylviaBrost,1 NielsSteinebrunner,2 Markus B¨ uchler,3
Peter Schemmer,3 andMartinaM¨ uller1
1Department of Gastroenterology, Endocrinology, Rheumatology and Infectious Diseases,
University Hospital Regensburg, D-93053 Regensburg, Germany
2Department of Gastroenterology, University Hospital Heidelberg, D-69120 Heidelberg, Germany
3Department of General and Transplant Surgery, University Hospital Heidelberg, D-69120 Heidelberg, Germany
Correspondence should be addressed to Kilian Weigand, kilian.weigand@ukr.de
Received 18 February 2012; Accepted 5 April 2012
Academic Editor: John J. Lemasters
Copyright © 2012 Kilian Weigand et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Liver ischemia/reperfusion (IR) injury is caused by a heavily toothed network of interactions of cells of the immune system,
cytokine production, and reduced microcirculatory blood ﬂow in the liver. These complex networks are further elaborated by
multiple intracellular pathways activated by cytokines, chemokines, and danger-associated molecular patterns. Furthermore,
intracellular ionic disturbances and especially mitochondrial disorders play an important role leading to apoptosis and necrosis of
hepatocytesinIRinjury.Overall,enhancedproductionofreactiveoxygenspecies,foundveryearlyinIRinjury,playsanimportant
role in liver tissue damage at several points within these complex networks. Many contributors to IR injury are only incompletely
understood so far. This paper tempts to give an overview of the diﬀerent mechanisms involved in the formation of IR injury.
Only by further elucidation of these complex mechanisms IR injury can be understood and possible therapeutic strategies can be
improved or be developed.
1.Introduction
Ischemia/reperfusion (IR) injury of the liver results from a
loss of blood supply reducing oxygen supply to the organ.
Upon revascularisation the liver undergoes reperfusion
injury. Together these factors lead to aﬀection of oxygen-
dependent cells within the liver causing impairment of
organ function. Aﬀected are all cells requiring mitochondrial
oxidative phosphorylation for their metabolism [1]. Warm
IR injury can be separated from cold IR injury. Warm
IR injury occurs during prolonged surgical liver resection
using clamping of the perfusion [2]. Other aetiologies
are reduced liver perfusion due to shock, heart failure,
respiratory failure, hemorrhage, trauma, and sepsis [3–5]. In
contrast, cold IR injury follows liver transplantation with the
necessity of cold preservation of the donor organ, followed
by reperfusion after implantation [6, 7]. Furthermore, it has
been demonstrated that tissue damage occurs in two phases,
an early and a late phase [8, 9]. The early phase which occurs
within the ﬁrst 6 hours following reperfusion is thought to
be the consequence of the fast change in the redox state of
the liver tissue [9, 10]. Most likely, this change is caused by
hepatocytes, Kupﬀer cells (KCs), and sinusoidal endothelial
cells (SECs) [8, 9, 11]. In contrast, the late phase of IR injury
is caused by the production of cytokines and chemokines
followed by the inﬁltration of leukocytes into the liver tissue
[8, 9, 12].
Of clinical relevance is that liver IR injury results in
elevatedliverenzymes,biliarystrictures,clinicaldysfunction,
or even liver failure [13]. Furthermore, other organs can
develop dysfunction secondary to the liver damage. Possible
aﬀected organs are lungs, heart, kidneys, and blood vessels
[14–17]. Risk factors for IR injury include age of the liver,
sex and others [18–21].
A complex network and cross talk of multiple molecular
mechanisms and cellular interactions lead to liver IR injury
[22, 23]. The result of these processes is cell death by
apoptosis and necrosis via diﬀerent pathways. Redox status,2 HPB Surgery
cellular ionic disturbances, cytokines, chemokines, other
mediators and molecular mechanisms as well as many
diﬀerent cells like KC, SEC, dendritic cells, leukocytes, and
lymphocytes are involved in this process and are closely
interlocked. Therefore, there are still many open questions
regarding this inﬂammatory response. This paper tempts to
g i v eas y s t e m a t i co v e r v i e wo ft h ed i ﬀerent components and
signalling pathways leading to IR injury.
2.AlteredRedoxStatusandReduced
MicrocirculatoryBlood Flow
IR injury starts with reduced blood ﬂow and a lack of
oxygen supply [24, 25]. This ischemia leads to a lack of
adenosine triphosphate (ATP) production in hepatocytes,
KC, and SEC [26]. As a result the function of the ATP-
dependent sodium/potassium plasma membrane pump
(Na+/K+ ATPase) is impaired. This results in an increase
of intracellular Na+, which is followed by a swelling of the
hepatocytes,KCandSEC.Narrowing ofthesinusoidals isthe
consequence. Within minutes after reperfusion, enhanced
levels of reactive oxygen species (ROS), such as superoxide
(O2
−), hydrogen peroxide (H2O2) and hydroxyl radical
(OH￿), can be measured [8, 9, 11, 27]. Cellular sources
for these ROS are mitochondrial metabolism, hepatocyte-
derived xanthine oxidase, and KC- and SEC-associated
NADPHoxidase[8,9,11,28].ThisincreaseofROSisaccom-
panied by reduced nitric oxide (NO), most likely due to a
decreased function of the NO synthase (NOS) in SEC [29,
30]. Since NO is a vasodilator [31], reduced NO aggravates
the sinusoidal narrowing. However, these mechanisms are
still controversially discussed [32, 33]. Especially the role of
the diﬀerent NOS isoforms is still unclear [34]. The eﬀects of
NO are well known. It increases the sinusoidal diameter and
increases intrahepatic ATP levels via better oxygen supply.
Thereby mitochondrial damage and leukocyte inﬁltration
are reduced. Since NO is synthesized by NOS, NOS should
be protective in IR injury. While this is well observed for
the endothelial NOS (eNOS), the role of the inducible NOS
(iNOS) is less clear [34]. In the late phase of IR injury it
probablyisalsoprotective,whileintheearlyphase,theremay
be a harmful role of iNOS.
Nevertheless, the changes occurring in IR injury lead to a
more oxidative environment with the ROS leading to both,
apoptotic and necrotic cell death of hepatocytes and SEC
[35, 36]. ROS causes damage to membrane lipids resulting
in cell swelling and death [35]. The damage is not limited
to the plasma membrane but includes cell organelles and
extracellular matrix. Besides swelling of cells and reduced
NO levels, the described damage leads to an increase of
vasoconstrictors like endothelin and thromboxane A2 [37].
In addition, adhesion and aggregation of platelets and
leucocytes is increased (see below). This leads to further
narrowing of the sinusoidals with signiﬁcant reduction of
microcirculatory blood ﬂow including areas with complete
absence of blood ﬂow [38], enhancing the lack of oxygen
supply. Increased ROS and decreased NO levels play further
roles which will be discussed below.
3. Ionic andMitochondrial Disturbances
In IR injury signiﬁcant changes of intracellular Ca2+ con-
centration in the hepatocytes can be found [39]. Ca2+ is
mainly found in three cellular compartments, in the cytosol,
the mitochondria, and the endoplasmic reticulum (ER). The
homeostatic concentration is regulated by diﬀerent Ca2+
channels. In IR injury cytosolic Ca2+ concentration is
increased as a result of increased entry across the plasma
membraneandreleasefromtheER.Reasonforthiscytoplas-
mic Ca2+ overload is the activation of the ryanodine receptor
in the ER membrane and the so-called transient receptor
potential (TRP) channels in the plasma membrane. There is
evidence that ROS can activate these channels [40, 41]. Sec-
ondary to decreased Ca2+ concentration in the endoplasmic
reticulum so-called store operated calcium (SOC) channels
in the plasma membrane further increase Ca2+ inﬂux [42,
43]. In addition, in IR injury the Ca2+ ATPase in ER and
plasma membrane is inhibited, potentially because of ATP
depletion. Normally this Ca2+ ATPase discharges cytosolic
Ca2+ into extracellular space and into the ER counteracting
the above mentioned Ca2+ channels [44].
Increased cytosolic Ca2+ leads to stimulation of the Ca2+
uniporter in the mitochondrial membrane [45]. As a result
the mitochondrial Ca2+ concentration increases as well. The
mechanism how the mitochondrial Ca2+ uniporter is acti-
vated has not been fully resolved, so far. It is believed
that the mitochondrial P2Y-like receptor 1 (mP2Y1)i s
activated by adenosine diphosphate (ADP) and adenosine
monophosphate (AMP). The mP2Y1 stimulates the PLC-
dependent mP2Y-like receptor resulting in activation of the
Ca2+ uniporter[46,47].Incontrast,mP2Y2 activatedbyATP
leads to inhibition of the uniporter. During IR injury ATP is
depleted,asdiscussedbefore,possiblyleadingtoactivationof
the uniporter. As a consequence of this increased mitochon-
drial Ca2+ concentration the mitochondrial transmembrane
potential is reduced. To maintain the mitochondrial mem-
brane the mitochondrial ATP-synthase reverses its activity
and hydrolyzes ATP to provide energy for diﬀerent ionic
pumps in the mitochondrial membrane [39]. However, this
further increases Ca2+ inﬂux resulting in ATP consumption
instead of production in the mitochondria. This is enhanced
by the fact that ROS causes oxidative damage to the enzymes
of the respiratory chain in the mitochondria leading to
failure of ATP production [48]. Cytosolic and mitochondrial
Ca2+ and other ionic disturbance lead to damage of plasma
and mitochondrial membranes including the formation and
opening of mitochondrial permeability transition (MPT)
pores [49]. MPT pores are formed from integral not fully
identiﬁed mitochondrial membrane proteins [50, 51]. Hep-
atic mitochondria aﬄicted by MPT pores are permanently
damaged due to depolarization of the mitochondria [37].
When only a few mitochondria are aﬄicted, they are
removed from the hepatocyte by lysosomal mitophagy [52].
Such damaged mitochondria are a source for further ROSHPB Surgery 3
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Figure 1: Intracellular signalling pathways and ionic disturbances engaged during IR injury, resulting in cellular swelling, apoptosis, and
necrosis. ADP: adenosine diphosphate; AMP: adenosine monophosphate; AP-1: activator protein-1; ATP: adenosine triphosphate; DAMP:
danger-associated molecular pattern; HMGB-1: high mobility group box-1; ICAM-1: intercellular adhesion molecule-1; IL-1: interleukin-1;
JNK: c-Jun N-terminal kinase; MAPK: mitogen-activated protein kinase; MPT pore: mitochondrial permeability transition pore; MyD88:
myeloid diﬀerentiation factor 88; NF-κB: nuclear factor kappa B; RAGE: receptor for advanced gylcation end product; ROS: reactive oxygen
species; SOC: store operated calcium channel; TLR: toll-like receptor; TNF: tumor necrosis factor; TRAM: TRIF-related adaptor molecule;
TRIF: TIR domain-containing adaptor inducing interferon; TRP: transient receptor protein; VCAM-1: vascular adhesion molecule-1.
production and ATP consumption [53]. However, ROS
themselves induce MPT pore opening. With the number of
damaged mitochondria increasing, cytochrome C is released
from the mitochondria into the cytosol triggering apoptosis
[48]. When the majority of the mitochondria within the
hepatocyte are aﬄicted by MPT pores ATP levels drop too
fast resulting in cell death by necrosis [49, 54].
Other important ionic disturbances in IR injury include
intracellular Na+ and hydrogen (H+) concentrations. Lack
of oxygen supply leads to anaerobic respiration of the hep-
atocytes resulting in intracellular acidosis [55]. To stabilize
intracellular pH within normal range the Na+/H+ exchanger
is activated by the hepatocytes, resulting in reduced cytosolic
H+ and further increased Na+ levels. In addition, the Na+/K+
exchanger is ATP dependent, so ATP depletion, as in IR
injury, subsequently blocks this exchange leading to further
increase of intracellular Na+ concentration resulting in cell
death [56].
Furthermore, this counteracts the protective eﬀect of
an acidic pH during reperfusion [57], for example, the
maintenance of an acidic pH prevents the formation of MPT
pores [49]. However, these regulations are still based on
experimental observations and need to be studied further to
understand the relevance in IR injury (Figure 1).
4.CellularCascadeinIRInjury
Many diﬀerent cell types are involved in the process of
hepatic damage and cell death in IR injury. The key cells
initiating IR injury are the KCs [58–60]. Besides their direct
damagebyROS,asdiscussedabove,theyarealsoactivatedby
ROS leading to production of more ROS and thereby enter-
ing a cycle of self-activation and -destruction. In addition,
KC are activated by the systemic complement system [61]
which may also be liberated by damaged hepatocytes. In
addition, complement leads to further liver damage by
formation of a membrane attack complex in the plasma
membrane, lysing liver cells [62].
Activated KCs also produce proinﬂammatory cytokines
includinginterleukin-1β(IL-1β)andtumornecrosisfactor-α
(TNF-α)[ 63]. These cytokines lead to activation and migra-
tion of neutrophils and CD4+ T lymphocytes into the liver
[64]. Furthermore, these cytokines stimulate SEC and hepa-
tocytes to produce ROS and to express adhesion molecules
on the cell surface [65]. As described above, this leads to
adhesion and aggregation of leucocytes and platelets [66],
inﬂuencing the microcirculatory blood ﬂow in the liver.
The recruitment of neutrophils and CD4+ T lympho-
cytes is further enhanced by the matrix metalloproteinase4 HPB Surgery
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Figure 2: Cellular interaction involved in IR injury, resulting in cellular swelling, apoptosis, and necrosis. ATP: adenosine triphosphate;
ICAM-1: intercellular adhesion molecule-1; KC: Kupﬀer cell; IL-1, interleukin-1; NKT: natural killer T cell; NO: nitric oxide; ROS: reactive
oxygen species; SEC: sinusoidal endothelial cells; T cell: CD4+ T lymphocyte; TNF: tumor necrosis factor; VCAM-1: vascular adhesion
molecule-1.
9[ 67] after ischemic damage of the liver. Via production
of interferon-γ (IFN-γ) and IL-17 by activated CD4+ T
lymphocytes additional activation of KC and hepatocytes
is achieved [68, 69]. Thus CD4+ T lymphocytes and KC
reciprocally activate each other [64]. These chemokines
furthermore activate natural killer T (NKT) cells. Activated
NKT cells directly damage liver tissue and also produce IFN-
γ with further activation of KC and hepatocytes [69, 70].
The net result of this circular activation and stimulation of
diﬀe r e n tc e l ls u bt yp e si sd e s t r u c t i o no fh e p a t o c yt e sa n dS E C
[71, 72].
The expressed cell-surface adhesion molecules on hep-
atocytes and SEC include intercellular adhesion molecule-
1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1)
[28, 73]. Neutrophils bind to ICAM-1 and VCAM-1 and
by doing so migrate across the endothelium into the liver
parenchyma enhancing ROS production and degranula-
tion of cytoplasmic vesicles containing enzymes capable to
degradeextracellularmatrixandhepatocytes[28](Figure 2).
5.DeathSignallingPathways
Besides direct damage of hepatocytes by neutrophils, NKT
cells, the complement system and ROS, the main destruction
of cells is mediated by endogeneous pathways leading to
apoptosis or necrosis of hepatic cells during IR injury.
Thispaperisnotcapabletofocusonallcytokinecascades
with pro- and antiinﬂammatory eﬀects [74]a sw e l la st h e i r
eﬀect during IR injury, but will concentrate on some impor-
tant signalling pathways. The most important component in
IR injury seems to be TNF-α [75, 76]. The pathways leading
to up regulation of TNF-α have been described above. TNF-
α binds to speciﬁc TNF-receptors, as for example TNF-
R1 and TNF-R2, on the hepatocyte surface which leads to
increased production of cytokines and ROS. In addition,
activation of CD95 leads to apoptosis [77–79]. Furthermore,
CD95 also binds NKT cells leading to direct destruction of
hepatocytes [80].
Furthermore, downstream of the receptor the nuclear
factor kappa B (NF-κB), the mitogen-activated protein
kinase (MAPK) and c-Jun N-terminal kinase (JNK) are
activated [81–83]. The various cytokines and the mentioned
molecules lead to alteration of various factors further
downstream like transcription factors, activator protein-1
(AP-1), heat shock factor, signal transducer and activa-
tors of transcription (STATs), antioxidants, inﬂammation-
stimulated inducible enzymes (COX-2), intracellular sig-
nalling molecules, antiapoptotic proteins (Bcl-2, Bcl-x), andHPB Surgery 5
many more [37]. The damage in IR injury therefore spreads
throughout the entire cell. NF-κB furthermore upregulates
the expression of cytokines, like TNF-α [84], and of ICAM-
1 and VCAM-1 [75, 82], enhancing the recruitment of
neutrophils. AP-1 promotes apoptosis of liver cells by
activation of caspase-3 and release of cytochrome C [82].
ROS furthermore inherit a direct oxidative damage of
DNAwithinthenucleusresultinginfurtherfailureofprotein
transcription and translation. In addition, ROS cause post-
translational protein modiﬁcation [85]. These alterations
a n dp a t h w a y sl e a dt oa p o p t o s i so ft h ed a m a g e dc e l l s .
The intracellular damage and alterations as well as the
damage of extracellular matrix are followed by the release
ofdanger-associatedmolecularpatterns(DAMPs).Examples
of DAMPs released during IR injury are the nuclear tran-
scription factor high mobility group box-1 (HMGB-1), the
cytoplasmic Ca2+ regulator S100, ATP, DNA, and hyaluronic
acid [86–90]. DAMPs bind to a group of so-called pattern
recognition receptors (PRRs) on the cell surface as well as
in the cytoplasm [37]. In IR injury mainly two PRRs are
involved, the toll-like receptors (TLRs), speciﬁcally TLR-
4 ,a n dt h er e c e p t o rf o ra d v a n c e dg l y c a t i o ne n dp r o d u c t s
(RAGE).TopresentknowledgeTLR-4providesanimportant
link between liver damage and activation of the immune
system. Activation of TLR-4 triggers intracellular signalling
cascades in IR injury [91]. The Toll-IL-1 receptor domain
(TIR) of TLR-4 interacts with intracellular adaptors. One
maybethemyeloiddiﬀerentiationfactor88(MyD88),others
are TIR domain-containing adaptor inducing interferon-β
(TRIF), and TRIF-related adaptor molecule (TRAM) [92].
Via production of proinﬂammatory cytokines the inﬂam-
matory response is mediated leading to liver IR injury [91–
93]. Included in the downstream process of these activation
are further transcription factors like NF-κB, AP-1, STAT, the
MAP kinase JNK, and ROS [86, 94–96].
The best characterized DAMP is HMGB-1 which is
expressedbyallnucleatedcellswithintheliverandisreleased
upon necrosis and apoptosis [86, 97]. HMGB-1 binding to
RAGE in IR injury leads to a signalling cascade involving
activation of JNK and other kinases, increasing expression
and activation of the inducible transcription factor early
growth response-1. As a consequence the upregulation of
several gene families is found, recruiting immune cells into
the post ischemic liver [98]. RAGE is mainly expressed on
dendritic cells and to lesser extent on KC [98]. Furthermore,
dendritic cells and KC also express TLR-4 [99]. This hints to
an important, but at present unclear, function of dendritic
cells during IR injury of the liver.
This complex communication of the described networks
is responsible to initiate and propagate IR injury.
6. Conclusions
The understanding of the molecular mechanisms underlying
cell death in hepatic IR injury will provide the basis for the
development of new strategies for inhibition of liver injury
and improvement of survival of the graft. The initial phase of
IR injury involves the release of ROS and proinﬂammatory
mediators by KC. ROS lead to oxidative damage, induction
ofp53,apoptosisandnecrosisofhepatocytesandendothelial
cells. The late phase (6–48 hours after reperfusion) is char-
acterized by neutrophil-mediated inﬂammatory responses.
Thus, proteins regulating the cellular redox equilibrium,
p53-dependent apoptosis and cellular death receptors repre-
sent potential targets for novel pharmaceutical interventions
to protect hepatocytes from IR injury-induced cell death.
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